Official Title
Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19
Brief Summary

(a) Objectives 1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years. 2. To assess the longevity of the serology response to SARS-CoV2. 3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model 4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines. 5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)

Detailed Description

The health conditions of adults (N=300) who recovered from varying severity of COVID-19 will
be assessed and their blood are collected at 6, 12, 24 and 36 months after discharge. The
assessment package includes: lung function tests, 6-min walk distance, chest radiographs/CT,
and SF36 General Health questionnaire. Blood samples from community cohorts will be collected
from before and up to 36 months after receiving one of the three COVID-19 vaccines (N=200 per
vaccine type). The kinetics of SARS-CoV-2 specific humoral and cellular immunities from both
convalescent and vaccinated cohorts are determined by neutralization assay and by measuring
specific T cell responses upon stimulation of SARS-CoV-2 specific peptide library
respectively. The antiviral level of the human plasma with various neutralization titer
collected from different vaccinated cohorts will be tested in mouse model and ADCC assay.

Recruiting
Lung Function
Exercise Capacity
Quality of Life
COVID19

Biological: third dose vaccination with CoronaVac vaccine

Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine

Biological: third dose vaccination with BionTech vaccine

Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine

Biological: Vaccination with Coronavac vaccine

Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart

Biological: Vaccination with BionTech Vaccine

Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart

Eligibility Criteria

Inclusion Criteria: Patients who have been discharged from hospital following treatment for
COVID-19 -

Exclusion Criteria: Unwilling to be follow up

-

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Hong Kong
Locations

Prince of Wales Hospital
Hong Kong, Hong Kong

Investigator: Susanna So-Shan Ng
Contact: 3505 2785
drsssng123@yahoo.com.hk

Contacts

Susanna Ng, MBChB
85235053128
drsssng@gmail.com

Karen Yiu, BSc
85235053532
ysyiu@cuhk.edu.hk

David S Hui, MD, Principal Investigator
Chinese University of Hong Kong

Chinese University of Hong Kong
NCT Number
MeSH Terms
COVID-19
Vaccines